Pfizer (PFE) Net Cash Flow (2009 - 2026)
Pfizer (PFE) posted quarterly Net Cash Flow of $544.0 million for Q1 2026, up 42.41% year-over-year from $382.0 million in Q1 2025, and up 369.31% quarter-over-quarter from -$202.0 million in Q4 2025.
Pfizer (PFE) Net Cash Flow (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Net Cash Flow for 18 consecutive years, with $544.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 42.41% year-over-year to $544.0 million; the TTM figure through Mar 2026 stood at $211.0 million (up 121.4% YoY), while the FY2025 annual figure was $49.0 million, up 102.81% from the prior year.
- Net Cash Flow improved to $544.0 million in Q1 2026 per PFE's latest filing, from -$202.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $1.8 billion in Q2 2023 and bottomed at -$2.1 billion in Q1 2024.
- Historically, Net Cash Flow has averaged -$81.1 million across 5 years, with a median of $173.0 million in 2025.
- Annual changes were most pronounced in 2022 — Net Cash Flow jumped 3412.5% — and 2024, when it plunged 220.1%.
- Pfizer's Net Cash Flow stood at -$623.0 million in 2022, then surged by 49.6% to -$314.0 million in 2023, then tumbled by 450.32% to -$1.7 billion in 2024, then surged by 88.31% to -$202.0 million in 2025, then jumped by 369.31% to $544.0 million in 2026.
- Business Quant data shows PFE's Net Cash Flow at $544.0 million in Q1 2026, -$202.0 million in Q4 2025, and -$304.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.89 Bn | 632.13 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 470.43 Bn | 463.86 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 375.74 Bn | 368.60 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 302.99 Bn | 295.30 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 257.51 Bn | 252.61 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 237.06 Bn | 223.07 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 182.88 Bn | 179.70 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 160.14 Bn | 148.44 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 106.08 Bn | 101.91 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Sanofi | 55.21 Bn | 47.83 Bn | 10.79 Bn | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -722.00 Mn |
| Jun 28, 2026 | -722.00 Mn |
| Mar 29, 2026 | 544.00 Mn |
| Mar 29, 2026 | 544.00 Mn |
| Dec 31, 2025 | -202.00 Mn |
| Dec 31, 2025 | -202.00 Mn |
| Sep 28, 2025 | -304.00 Mn |
| Sep 28, 2025 | -304.00 Mn |
| Jun 29, 2025 | 173.00 Mn |
| Jun 29, 2025 | 173.00 Mn |
| Mar 30, 2025 | 382.00 Mn |
| Mar 30, 2025 | 382.00 Mn |
| Sep 29, 2024 | -1.73 Bn |
| Sep 29, 2024 | -1.73 Bn |
| Jun 30, 2024 | 360.00 Mn |
| Jun 30, 2024 | 360.00 Mn |
| Mar 31, 2024 | -2.11 Bn |
| Mar 31, 2024 | -2.11 Bn |
| Dec 31, 2023 | -314.00 Mn |
| Dec 31, 2023 | -314.00 Mn |